AU2020266947B2 - Method for treating endometriosis-associated pain by using diaminopyrimidine compound - Google Patents

Method for treating endometriosis-associated pain by using diaminopyrimidine compound

Info

Publication number
AU2020266947B2
AU2020266947B2 AU2020266947A AU2020266947A AU2020266947B2 AU 2020266947 B2 AU2020266947 B2 AU 2020266947B2 AU 2020266947 A AU2020266947 A AU 2020266947A AU 2020266947 A AU2020266947 A AU 2020266947A AU 2020266947 B2 AU2020266947 B2 AU 2020266947B2
Authority
AU
Australia
Prior art keywords
days
compound
alkylene
saturated
nrarb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020266947A
Other languages
English (en)
Other versions
AU2020266947A1 (en
Inventor
Ran AN
Huai HUANG
Yuanyuan JIANG
Zhou LAN
Huining LIANG
Yanan Liu
Hongjun Wang
Jin Wang
Yanping Zhao
Liying Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of AU2020266947A1 publication Critical patent/AU2020266947A1/en
Application granted granted Critical
Publication of AU2020266947B2 publication Critical patent/AU2020266947B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020266947A 2019-04-30 2020-04-29 Method for treating endometriosis-associated pain by using diaminopyrimidine compound Active AU2020266947B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/085209 2019-04-30
CN2019085209 2019-04-30
PCT/CN2020/087689 WO2020221277A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法

Publications (2)

Publication Number Publication Date
AU2020266947A1 AU2020266947A1 (en) 2021-12-16
AU2020266947B2 true AU2020266947B2 (en) 2025-10-09

Family

ID=73028778

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020266947A Active AU2020266947B2 (en) 2019-04-30 2020-04-29 Method for treating endometriosis-associated pain by using diaminopyrimidine compound

Country Status (12)

Country Link
US (1) US12605381B2 (enExample)
EP (1) EP3960178B1 (enExample)
JP (1) JP7663508B2 (enExample)
KR (1) KR102935431B1 (enExample)
CN (1) CN114007620B (enExample)
AU (1) AU2020266947B2 (enExample)
BR (1) BR112021021838A8 (enExample)
CA (1) CA3138238A1 (enExample)
MX (1) MX2021013347A (enExample)
SG (1) SG11202111960PA (enExample)
TW (1) TWI737285B (enExample)
WO (1) WO2020221277A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途
WO2023081800A1 (en) * 2021-11-05 2023-05-11 The Regents Of The University Of California Alpha-2a adrenergic receptor modulators and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
CN108779119A (zh) * 2016-03-25 2018-11-09 传入制药公司 嘧啶及其变体、及其用途
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途
WO2019085916A1 (zh) * 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途
CN108779119A (zh) * 2016-03-25 2018-11-09 传入制药公司 嘧啶及其变体、及其用途
WO2019085916A1 (zh) * 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. S. Carter, et al. Bioorganic & Medicinal Chemistry Letters. 2009, 19(6): 1628-1631. DOI: 10.1016/j.bmcl.2009.02.003. *
G. Burnstock; "Purinergic mechanisms and pain - an update", European Journal of Pharmacology. 2013, 716(1): 24-40. DOI: 10.1016/J.EJPHAR.2013.01.078. *
S. Ding, et al.; "P2X3 receptor involvement in endometriosis pain via ERK signaling pathway", PLoS One. 2017, 12(9): 1-17. DOI: 10.1371/journal.pone.0184647. *

Also Published As

Publication number Publication date
WO2020221277A1 (zh) 2020-11-05
KR102935431B1 (ko) 2026-03-05
JP7663508B2 (ja) 2025-04-16
MX2021013347A (es) 2022-01-24
CN114007620A (zh) 2022-02-01
CA3138238A1 (en) 2020-11-05
SG11202111960PA (en) 2021-12-30
BR112021021838A8 (pt) 2023-02-28
BR112021021838A2 (pt) 2022-01-04
US12605381B2 (en) 2026-04-21
JP2022531570A (ja) 2022-07-07
AU2020266947A1 (en) 2021-12-16
KR20220008286A (ko) 2022-01-20
EP3960178A1 (en) 2022-03-02
US20220249478A1 (en) 2022-08-11
TW202106303A (zh) 2021-02-16
TWI737285B (zh) 2021-08-21
CN114007620B (zh) 2024-08-06
EP3960178B1 (en) 2026-03-18
EP3960178A4 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
AU2020230574B2 (en) Method for treating fatty liver disease and/or steatohepatitis
AU2020305979B2 (en) Method for treating idiopathic pulmonary fibrosis
AU2020266947B2 (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
KR20140099492A (ko) 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
CZ289533B6 (cs) Pouľití dihydropyridinových derivátů s anelovanými uhlíkovými nebo heterocyklickými kruhy pro výrobu farmaceutických prostředků k ochraně mozkové tkáně
AU2020265327B2 (en) Method for treating cough by using diaminopyrimidine compound
HK40062123A (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
US7354949B2 (en) Therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia
US20100331340A1 (en) Use of aryl piperazine derivatives in manufacturing medicants for treating pain
HUP0203790A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére
US20040106671A1 (en) Remedies for vesical hyperesthesia
HK40063619A (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
US4612310A (en) Antirheumatically active suppositories
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
US3177118A (en) Camphorated derivatives of 2-aminothiazoline for analeptic and antitussive activity
NZ217755A (en) 2-(2-thienyl)-imidazo(4,5-c)pyridine derivatives and pharmaceutical compositions
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis
NL8006341A (nl) Voor roentgenstralen amorfe, fysiologisch toelaatbare zuuradditiezouten van ergotalkaloiden en dihydroer- gotalkaloiden, werkwijze voor de bereiding en toepas- sing daarvan in de therapie.
DE2144225A1 (de) Verfahren zur Herstellung von neuen Theophyllinisobutyratsalzen
JPWO1998027982A1 (ja) アスコルビン酸含有組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)